Table 4.

Association of clinical variables with the risk of primary endpoint.

	Non-AMI (n = 7599)		AMI (n = 3136)
	HR (95% CI)	P	HR (95% CI)	P
Age, year	1.05 (1.04–1.07)	< 0.001	1.05 (1.03–1.06)	< 0.001
Male	1.11 (0.87–1.43)	0.398	0.81 (0.61–1.07)	0.136
Hypertension	1.54 (1.19–2.00)	0.001	1.57 (1.19–2.06)	0.001
Diabetes	1.32 (1.05–1.67)	0.019	1.42 (1.08–1.86)	0.013
Dyslipidemia	1.13 (0.88–1.45)	0.342	0.98 (0.74–1.30)	0.906
Obesity	0.55 (0.43–0.71)	< 0.001	0.51 (0.37–0.70)	< 0.001
Smoking	0.73 (0.54–0.98)	0.038	0.77 (0.58–1.02)	0.065
Chronic kidney disease	2.30 (1.81–2.92)	< 0.001	2.28 (1.74–2.99)	< 0.001
HF	2.73 (1.80–4.13)	< 0.001	3.84 (2.75–5.35)	< 0.001
HPR	1.40 (1.11–1.78)	0.005	1.38 (1.05–1.80)	0.019
High AIP	0.78 (0.61–1.00)	0.050	0.89 (0.67–1.19)	0.437
Multivessel disease	1.11 (0.88–1.41)	0.373	1.53 (1.17–2.01)	0.002
Bifurcation lesion	1.13 (0.83–1.56)	0.433	1.15 (0.80–1.64)	0.451
CTO lesion	1.13 (0.75–1.70)	0.565	1.71 (1.08–2.70)	0.023
Number of stents	1.09 (0.95–1.25)	0.209	1.14 (0.97–1.35)	0.113
Total length of stent, mm	1.00 (0.99–1.01)	0.104	1.00 (0.99–1.01)	0.149
Minimal diameter of stent, mm	0.63 (0.47–0.84)	0.001	0.87 (0.65–1.15)	0.321
Beta blocker	1.23 (0.97–1.56)	0.082	0.83 (0.62–1.11)	0.213
Angiotensin blockade	1.15 (0.91–1.46)	0.244	1.18 (0.87–1.59)	0.293
Calcium channel blocker	1.21 (0.94–1.56)	0.148	0.99 (0.69–1.41)	0.946
Statin	1.21 (0.84–1.74)	0.309	0.94 (0.62–1.44)	0.789

HF was defined as a reduced LVEF less than 40%

AIP atherogenic index of plasma; AMI acute myocardial infarction; BMI body mass index; CI confidence interval; CTO chronic total occlusion; HF heart failure; HPR high platelet reactivity; HR hazard ratio; LVEF left ventricular ejection fraction.